Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons
- PMID: 20713152
- DOI: 10.1016/j.bbadis.2010.08.006
Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons
Abstract
Parkinson's disease (PD) involves the loss of dopamine (DA) neurons, making it the most expected neurodegenerative disease to be treated by cell replacement therapy. Stem cells are a promising source for cell replacement therapy due to their ability to self-renew and their pluripotency/multipotency that allows them to generate various types of cells. However, it is challenging to derive midbrain DA neurons from stem cells. Thus, in this review, I will discuss the molecular factors that are known to play critical roles in the generation and survival of DA neurons. The developmental process of DA neurons and functions of extrinsic soluble factors and homeodomain proteins, forkhead box proteins, proneural genes, Nurr1 and genes involved in epigenetic control are discussed. In addition, different types of stem cells that have potential for future cell replacement therapy are reviewed.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival.Stem Cells. 2010 Mar 31;28(3):501-12. doi: 10.1002/stem.294. Stem Cells. 2010. PMID: 20049900
-
Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease.Nature. 2002 Jul 4;418(6893):50-6. doi: 10.1038/nature00900. Epub 2002 Jun 20. Nature. 2002. PMID: 12077607
-
Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype.Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2874-9. doi: 10.1073/pnas.0511153103. Epub 2006 Feb 13. Proc Natl Acad Sci U S A. 2006. PMID: 16477036 Free PMC article.
-
Efficient induction of dopaminergic neurons from embryonic stem cells for application to Parkinson's disease.Yonsei Med J. 2004 Jun 30;45 Suppl:23-7. doi: 10.3349/ymj.2004.45.Suppl.23. Yonsei Med J. 2004. Retraction in: Yonsei Med J. 2004 Dec 31;45(6):1203. doi: 10.3349/ymj.2004.45.6.1203. PMID: 15250046 Retracted. Review.
-
Engineering a dopaminergic phenotype in stem/precursor cells: role of Nurr1, glia-derived signals, and Wnts.Ann N Y Acad Sci. 2005 May;1049:51-66. doi: 10.1196/annals.1334.007. Ann N Y Acad Sci. 2005. PMID: 15965107 Review.
Cited by
-
Comparison of ectopic gene expression methods in rat neural stem cells.Korean J Physiol Pharmacol. 2013 Feb;17(1):23-30. doi: 10.4196/kjpp.2013.17.1.23. Epub 2013 Feb 14. Korean J Physiol Pharmacol. 2013. PMID: 23439859 Free PMC article.
-
Neural Stem Cell Differentiation Using Microfluidic Device-Generated Growth Factor Gradient.Biomol Ther (Seoul). 2018 Jul 1;26(4):380-388. doi: 10.4062/biomolther.2018.001. Biomol Ther (Seoul). 2018. PMID: 29635911 Free PMC article.
-
Therapeutic effect of a histone demethylase inhibitor in Parkinson's disease.Cell Death Dis. 2020 Oct 28;11(10):927. doi: 10.1038/s41419-020-03105-5. Cell Death Dis. 2020. PMID: 33116116 Free PMC article.
-
Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.Transl Neurodegener. 2017 Oct 25;6:28. doi: 10.1186/s40035-017-0099-z. eCollection 2017. Transl Neurodegener. 2017. PMID: 29090092 Free PMC article. Review.
-
Advanced biomaterial strategies to transplant preformed micro-tissue engineered neural networks into the brain.J Neural Eng. 2016 Feb;13(1):016019. doi: 10.1088/1741-2560/13/1/016019. Epub 2016 Jan 13. J Neural Eng. 2016. PMID: 26760138 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical